Preclinical models of atherosclerosis. The future of Hybrid PET/MR technology for the early detection of vulnerable plaque. (8th April 2016)

• Record Type: Journal Article
• Authors: Cuadrado, Irene; Saura, Marta; Castejón, Borja; Martin, Ana María; Herruzo, Irene; Balatsos, Nikolaos; Zamorano, Jose Luis; Zaragoza, Carlos
• Is Part Of: Expert reviews in molecular medicine. Volume 18(2016)
• Publication Date: 2016-04-08
• Subjects: Molecular biology -- Periodicals; 616.042
• DOI: 10.1017/erm.2016.5
• Languages: English
• ISSNs: 1462-3994

Abstract

Abstract : Cardiovascular diseases are the leading cause of death in developed countries. The aetiology is currently multifactorial, thus making them very difficult to prevent. Preclinical models of atherothrombotic diseases, including vulnerable plaque-associated complications, are now providing significant insights into pathologies like atherosclerosis, and in combination with the most recent advances in new non-invasive imaging technologies, they have become essential tools to evaluate new therapeutic strategies, with which can forecast and prevent plaque rupture. Positron emission tomography (PET)/computed tomography imaging is currently used for plaque visualisation in clinical and pre-clinical cardiovascular research, albeit with significant limitations. However, the combination of PET and magnetic resonance imaging (MRI) technologies is still the best option available today, as combined PET/MRI scans provide simultaneous data acquisition together with high quality anatomical information, sensitivity and lower radiation exposure for the patient. The coming years may represent a new era for the implementation of PET/MRI in clinical practice, but first, clinically efficient attenuation correction algorithms and research towards multimodal reagents and safety issues should be validated at the preclinical level.